MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that Asterias has filed a registration statement with the Securities and Exchange Commission for an underwritten public offering of up to $15,000,000 of units with each unit consisting of one share of Series B common stock and one redemption right. The shares of Series B common stock and redemption rights will immediately be freely tradable as separate securities. The number of units to be sold and the price range for the proposed offering have not yet been determined.
Help employers find you! Check out all the jobs and post your resume.
